5000272025-01-012025-03-315000272025-03-315000272024-03-315000272024-04-012025-03-315000272025-01-012025-03-31in-capmkt:OtherExpenses1Member5000272025-01-012025-03-31in-capmkt:OtherExpenses2Member5000272024-04-012025-03-31in-capmkt:OtherExpenses1Member5000272024-04-012025-03-31in-capmkt:OtherExpenses2Member5000272025-01-012025-03-31in-capmkt:ReportableSegments1Member5000272025-01-012025-03-31in-capmkt:ReportableSegments2Member5000272025-01-012025-03-31in-capmkt:ReportableSegments3Member5000272024-04-012025-03-31in-capmkt:ReportableSegments1Member5000272024-04-012025-03-31in-capmkt:ReportableSegments2Member5000272024-04-012025-03-31in-capmkt:ReportableSegments3Member5000272025-01-012025-03-31in-capmkt:ReportableSegments1Member5000272025-01-012025-03-31in-capmkt:ReportableSegments2Member5000272025-01-012025-03-31in-capmkt:ReportableSegments3Member5000272024-04-012025-03-31in-capmkt:ReportableSegments1Member5000272024-04-012025-03-31in-capmkt:ReportableSegments2Member5000272024-04-012025-03-31in-capmkt:ReportableSegments3Member5000272025-01-012025-03-31in-capmkt:ReportableSegments1Member5000272025-03-31in-capmkt:ReportableSegments1Member5000272025-01-012025-03-31in-capmkt:ReportableSegments2Member5000272025-03-31in-capmkt:ReportableSegments2Member5000272025-01-012025-03-31in-capmkt:ReportableSegments3Member5000272025-03-31in-capmkt:ReportableSegments3Member5000272025-01-012025-03-31in-capmkt:ReportableSegments1Member5000272025-03-31in-capmkt:ReportableSegments1Member5000272025-01-012025-03-31in-capmkt:ReportableSegments2Member5000272025-03-31in-capmkt:ReportableSegments2Member5000272025-01-012025-03-31in-capmkt:ReportableSegments3Member5000272025-03-31in-capmkt:ReportableSegments3Member5000272025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15000272025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25000272025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss35000272024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15000272024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25000272024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss35000272025-01-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15000272025-01-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss25000272024-04-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15000272024-04-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss25000272025-01-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares500027ATULNOTLISTEDINE100A01010ATUL LIMITEDMain BoardEquity2024-04-012025-03-312025-04-252025-03-26INRCroresQuarterlyFourth quarterMulti segment2025-04-2510:30:002025-04-2514:00:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31UnauditedConsolidated14516400000487000000150034000007094200000246900000-3620000011887000005420000081710000037935000001315840000018450000000184500000037280000018680000055960000001285400000000159000001301300000-1926000000-624700000126500000036300000-661000000363000002944000001042.9742.970042.9742.97Consolidated financial results for the quarter / year ended on March 31, 2025 <BR> Notes: <BR> <BR> 1. These results have been prepared in accordance with the Indian Accounting Standard (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. <BR> <BR> 2. These results have been reviewed and recommended for adoption by the Audit Committee in its meeting held on April 24, 2025 and approved by the Board of Directors in its meeting held on April 25, 2025. The Statutory Auditors have expressed an unqualified audit opinion. <BR> <BR> 3. The Company has reported segment information as per the Ind AS 108, 'Operating Segments', as below: <BR> <BR> Name of segment Main product groups <BR> Life Science Chemicals Active pharmaceutical ingredients and its intermediates, crop protection chemicals <BR> Performance and Other Chemicals Adhesion promoters, bulk chemicals, epoxy resins and hardeners, intermediates, textile dyes <BR> Others Agribiotech, food products, services and others <BR> <BR> 4. Other expenses include ` 24.56 cr for the quarter ended on March 31, 2025 and ` 41.36 cr for the year ended on March 31, 2025 towards application fees, cess, premium, conversion charges, customary penal charges, non-agricultural assessment charges, differential stamp duty, etc, for converting part of the agricultural land to industrial use. <BR> <BR> 5. The figures of the last quarter represent the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial year. There are no material adjustments made in the results for the quarter ended on March 31, 2025, which pertain to earlier periods. These have been subjected to limited review by the Auditors. <BR> <BR> 6. The Board of Directors has recommended a dividend of ` 25 per share (250%) subject to the approval of the shareholders. <BR> 2024-04-012025-03-31AuditedConsolidated5583350000010903000005692380000028054200000701400000-1299500000454610000023980000031682000001470170000050111900000681190000006811900000158120000035540000019366000000487530000000011300000049883000005905000005578800000483930000014900000054298000001490000002944000001050690900000164.37164.3700164.37164.37Other Expenses (refer Note 4.)2292700000Power, fuel and water1500800000Other Expenses (refer Note 4.)8177700000Power, fuel and water6524000000279198000001243300000322000002914000001600000002140000005710000008925800000041000001728000009102700000214100000956700000405612000007292900000816270000011262600000513700000132900000057530000020647200000015086000002944870000000700099000002946000005569090000055985500000638200000566237000001820100000000976000001917700000368000000225330000009400000454840000015680000038390000057631000006147000000179740000081012000004739000002103000005240000008837800000001338620000070009900000Life Science Chemicals4438900000Performance and Other Chemicals10547200000Other171400000Life Science Chemicals16916700000Performance and Other Chemicals40582400000Other739200000151575000005823830000064110000024048000001451640000055833500000Life Science Chemicals965500000Performance and Other Chemicals855100000Other12100000Life Science Chemicals3467600000Performance and Other Chemicals3448500000Other1230000001832700000703910000054200000239800000-82400000-12560000018609000006924900000Life Science Chemicals13238200000Performance and Other Chemicals36461700000Other2226000000519259000001808400000070009900000Life Science Chemicals2852900000Performance and Other Chemicals7313700000Other25260000010419200000296700000013386200000239800000-1146200000-1506600000000000005626000000316820000000000120200000000-386900000000-17380000008773000007689200000-783000000-73400000150620000006031300000004260000032561000000000146000002701800000000000000000039000001150000000165900000108000000765500000-4950900000000000000005888000002367000000-10700000-8362000002442000008500000252700000602600000855300000Fair value of equity instruments through other comprehensive income-2261000000Remeasurement gain/(loss) on defined benefit plans-27400000Share of other comprehensive income of joint venture company accounted for using the equity method (net of tax)-100000-2288500000Fair value of equity instruments through other comprehensive income683900000Remeasurement gain/(loss) on defined benefit plans-9100000Share of other comprehensive income of joint venture company accounted for using the equity method (net of tax)-100000674700000-323600000159100000Effective portion of gain/(loss) on cash flow hedges7600000Exchange differences on translation of foreign operations3590000043500000Effective portion of gain/(loss) on cash flow hedges-2900000Exchange differences on translation of foreign operations72800000699000004600000-5000000-1926000000590500000AuditedtrueDeloitte Haskins and Sells LLPtrue2027-07-31